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Transcriptomic and ChIP-sequence
interrogation of EGFR signaling in HER2+
breast cancer cells reveals a dynamic
chromatin landscape and S100 genes as
targets
Miguel Nava1,2, Pranabananda Dutta1, Nathan R. Zemke3, Robin Farias-Eisner2, Jaydutt V. Vadgama1,2*
and Yanyuan Wu1,2*
Abstract
Background: The Human Epidermal Growth Factor Receptor (EGFR/HER1) can be activated by several ligands including
Transforming Growth Factor alpha (TGF-α) and Epidermal Growth Factor (EGF). Following ligand binding, EGFR
heterodimerizes with other HER family members, such as HER2 (human epidermal growth factor receptor-2).
Previously, we showed that the EGFR is upregulated in trastuzumab resistant HER2 positive (HER2+) breast
cancer cells. This study is aimed to determine the downstream effects on transcription following EGFR upregulation in
HER2+ breast cancer cells.
Methods: RNA-sequence and ChIP-sequence for H3K18ac and H3K27ac (Histone H3 lysine K18 and K27 acetylation) were
conducted following an Epidermal Growth Factor (EGF) treatment time course in HER2+ breast cancer cells, SKBR3. The
levels of several proteins of interest were confirmed by western blot analysis. The cellular localization of proteins of
interest was examined using biochemically fractionated lysates followed by western blot analysis.
Results: Over the course of 24 h, EGFR stimulation resulted in the modulation of over 4000 transcripts. Moreover,
our data demonstrates that EGFR/HER2 signaling regulates the epigenome, with global H3K18ac and H3K27ac
oscillating as a function of time following EGF treatment. RNA-sequence data demonstrates the activation of immediate
early genes (IEGs) and delayed early genes (DEGs) within 1 h of EGF treatment. More importantly, we have identified
members of the S100 (S100 Calcium Binding Protein) gene family as likely direct targets of EGFR signaling as H3K18ac,
H3K27ac and pol2 (RNA polymerase II) increase near the transcription start sites of some of these genes.
Conclusions: Our data suggests that S100 proteins, which act as Ca2+ sensors, could play a role in EGF induced tumor
cell growth and metastasis, contribute to trastuzumab resistance and cell migration and that they are likely drug targets
in HER2+ breast cancer.
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Background
Human Epidermal Growth Factor Receptor-2-positive
(HER2+) breast cancer is one of the four major molecu-
lar sub-types of breast cancer. HER2 is a classical re-
ceptor tyrosine kinase (RTK) and its kinase activity is
stimulated by heterodimerization with other ligand
bound HER family members, such as EGFR/HER1 [1–3].
Treatment for HER2+ breast cancer includes the use of
trastuzumab, a monoclonal antibody that binds to the
HER2 extracellular domain and inhibits downstream
signaling [4]. Primary or acquired resistance to trastuzu-
mab has been a major challenge for clinical management
of this disease. Resistance to trastuzumab may involve
intrinsic alternations in HER2 receptor (e.g. deletions of
the regions coding the trastuzumab binding site); loss of
antibody-dependent cell-mediated cytotoxicity (ADCC);
intracellular alterations in HER2 downstream signaling;
and crosstalk between receptors and signaling pathways
leading to activation of other HER family receptors, such
as EGFR [5].
EGFR binds to its cognate ligand EGF (Epidermal
Growth Factor) which induces receptor tyrosine phos-
phorylation and promotes cross talk between EGFR family
members and other signaling pathways. Aberrant EGFR
activity has been shown to play a key role in therapeutic
resistance [5, 6]. A previous study from our laboratory
demonstrated that HER2+ breast cancer cells resistant to
trastuzumab had higher levels of EGFR relative to con-
trols, which we hypothesized could amplify downstream
signaling and enhance migration [7]. Although the EGFR
signaling cascade has been studied extensively, several as-
pects still remain elusive.
The effects on transcription following activation of
EGFR have been studied in several cancer and non-can-
cer cell types and with the use of different metho-
dologies [8–14]. With the use of microarray technology
it was demonstrated that HeLa cells (cervical cancer
cells) stimulated with EGF exhibited waves of transcrip-
tion within a time course of 8 h [8]. Stimulation of
non-cancer breast cells, MCF10A with EGF activated
intracellular signal transduction pathways that lead to
the induction of genes involved in cell motility, in
addition to the activation of immediate early genes
(IEGs) [8, 9]. The same group also showed that EGF-reg-
ulated mRNA’s in MCF10A cells were modulated
post-transcriptionally by immediately down-regulated
microRNAs (ID-miRs), immediately up-regulated micro-
RNAs (IU-miRs) and delayed up-regulated microRNAs
(DU-miRs) [9, 13].
More recent publications have investigated EGFR-
modulated transcription utilizing Next Generation Se-
quencing (NGS) technologies [12, 14]. Interestingly, im-
mediate early genes (IEGs) are relieved of the “pause”
step in transcription by the recruitment of the Integrator
complex following EGF treatment of HeLa cells [12].
The Integrator complex is also involved in EGF stimula-
tion dependent biogenesis of enhancer RNAs (eRNAs)
[14]. Due to these results and more recent ones, the
Integrator complex has emerged as a novel putative drug
target in melanoma cell line, A375 and non-small cell
lung adenocarcinoma cell line, A549 [15]. However,
despite these findings, the effects on transcription
following long term EGF stimulation of EGFR (> 20min)
and its underlying chromatin basis remains unexplored in
HER2+ breast cancer cells.
In this study, we used Next Generation Sequencing
(NGS) technologies to determine the fluctuations in
gene expression following EGF treatment of SKBR3
(HER2+ breast cancer cells). We found that over 4000
transcripts are modulated by 2-fold or more during a 24
h EGF time course. In addition, we observed oscillations
in H3K18ac and H3K27ac during the same period. Sur-
prisingly, regardless of when transcript levels peak, all
activated genes gain H3K18ac and H3K27ac within 1 h
post EGF treatment, have a decrease in those marks 6 h
post-EGF treatment and regain those 24 h post-EGF
treatment. Lastly, we identified S100 genes, which have
been reported to contribute to tumorigenic processes
[16], as likely direct targets of EGFR/HER2 signaling.
S100 genes gradually increase in expression during an
EGF treatment time course, gain H3K18ac and H3K27ac
marks near their promoters and some also gain pol2
within 20 min of EGF treatment in HeLa cells.
Methods
Cell lines
The human breast cancer cell line SKBR3 (HTB-30) was
obtained from American Type Culture Collection. Mono-
layer cultures of the cells were maintained in DMEM/F12
medium with 10% fetal bovine serum. The cell line over-
expressed the HER2/c-erb-2 (HER2) gene product. The
SKBR3/100–8 line was generated from SKBR3 by clonal
selection after long term adaptation in maintained in
growth medium containing 100 μg/ml of trastuzumab in
our Laboratory. The clone was confirmed to be through
clone selection and confirmed remaining HER2 overex-
pression and insensitive to trastuzumab treatment [7].
Western blot
Protein lysates were prepared using EBC modified
buffer (50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.5%
NP-40) containing Thermo Scientific Protease and
Phosphatase Inhibitor Tablets (A32959). The following
antibodies were used: phospho-EGFR (Tyr1068) (Cell
Signaling Technology, Cat. 3777S), EGFR (Cell Signa-
ling Technology, Cat. 4267S), phospho-AKT (Cell Sig-
naling Technology, Cat. 9271S), AKT (Cell Signaling
Technology, Cat. 9272S), phospho-ERK1/2 (Thr202/
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Tyr204) (Cell Signaling Technology, Cat. 4370S),
ERK1/2 (Cell Signaling Technology, Cat. 4695S) and
β-actin (Santa Cruz Biotechnology, sc-69,875).
Quantitative-PCR
RNA was isolated using Trizol (ThermoFisher Scientific,
Cat. 15,596,026). 1μg of RNA was used to construct
libraries using iScript (Bio-Rad, Cat. 1,708,840). 1/20th
of reaction mix from constructed libraries was used in
each qPCR reaction using iTAC Universal SYBR Green
Supermix (Bio-Rad, Cat. 1,725,122). Primers used for
qRT-PCR can be found in Additional file 1: Table S3.
RNA-seq
The media from subconfluent SKBR3 cells was changed
from 10% FBS DMEM to 0.2% FBS DMEM 18–20 h
prior to the beginning of the EGF treatment time course.
EGF was added to a final concentration of 50 ng/mL for
indicated time intervals. RNA was isolated using Trizol
(ThermoFisher Scientific, catalog number 15596026).
Nanodrop and Qubit Fluorometric instruments were
used to determine RNA concentrations. 1μg of RNA was
used to construct libraries with KAPA mRNA Hyper-
prep Kit (Roche KK8580). Libraries were sequenced on
an Illumina Hiseq 3000 instrument.
RNA-seq analysis
Biological replicates (n = 2) mRNA-seq (single end 50
bp) reads were aligned to hg19 using default parameters
of Tophat2 (version 2.1.0) and Bowtie2 (version 2.3.2).
Samtools (version 0.1.18) was used to convert SAM to
BAM files. FPKM values were generated using default
parameters for Cuffdiff (version 2.1.1). Only FPKM
values greater than 0.5 were considered for further ana-
lysis. P-values for RNA-seq are reported as the output
files indicate (which are based on the Jensen-Shannon
metric).
ChIP-PCR
The same protocol for ChIP-seq was followed up to the
purification and quantitation of ChIP DNA (see below).
At that point, equal mass of ChIP and input DNA was
used in a qPCR reaction. Enrichment was determined by
dCt relative to input. Primers used in qPCR can be
found in Additional file 1: Table S3.
ChIP-seq
The media from subconfluent SKBR3 cells was changed
from 10% FBS DMEM to 0.2% FBS DMEM 18–20 h
prior to the beginning of the EGF treatment time course.
EGF was added to a final concentration of 50 ng/mL for
indicated times. Following EGF treatment time course,
formaldehyde was added to a final concentration of 1%
and incubated for 10 min at 37 °C. Following PBS
washing, cells were scraped and washed with 1 mL of
PBS containing protease inhibitors (Roche). Cells were
resuspended in lysis buffer at a ratio of 5 × 106 cells per
100ul of lysis buffer. 150ul of cell lysate was used in
chromatin immunoprecipitation with a given antibody.
10ul of cell lysate was saved for use as input. 3μg of
antibody (H3K18ac (EMD Millipore, catalog 07–354)
and H3K27ac (Active Motif, catalog 39,135)) was used
per ChIP. Following washes and elution, immunopreci-
pitated material was reverse crosslinked overnight at
65 °C. Samples were treated with RNase A for 30 min at
37 °C and then with Proteinase K for 2 h at 56 °C. DNA
was recovered using phenol/chloroform extraction and
precipitation. Qubit Fluorometric instrument was used
to quantify concentration of recovered DNA. 1 ng of
DNA was used to construct libraries with KAPA Hyper
Prep Kit (Roche KK8502). Libraries were sequenced on
an Illumina Hiseq 3000 instrument.
ChIP-seq analysis
Biological replicates (n = 2) single end 50 bp reads were
aligned to hg19 using default parameters of Bowtie2
(version 2.3.2). Only reads that aligned to a unique po-
sition in the genome with no more than two sequence
mismatches were retained for further analysis. Peaks
were identified with MACS2 (version 2.1.1) using default
parameters (q-value (minimum FDR) was 0.01 and
p-value < .0005). Q-values are calculated from p-values
using Benjamini-Hochberg method. MACS2 output
Bedgraph files were converted to BigWig using bed-
GraphtoBigWig. And BigWig files were converted to
Wiggle files for use in CEAS with bigWigtoWig (http://
hgdownload.soe.ucsc.edu). Integrated Genome Browser
(IGB) was used to view Bedgraph, BigWig and Wiggle
files (http://bioviz.org/igb/). Average H3K18ac and
H3K27ac enrichment near the TSS was determined using
Cis-regulatory Element Annotation System (CEAS)
(http://liulab.dfci.harvard.edu/CEAS/). Bedtools (version
2.26.0) intersect option was used to determine overlapping
peaks between H3K18ac or H3K27ac peaks at different
time points.
Transcription factor binding site (TFBS) query
Homer (version 4.9) (homer.ucsd.edu) was used to find
enriched motifs from − 300 to + 50 bp (default settings)
of each cluster in the RNA-seq data set. Only motifs that
were enriched with a p-value < .01 are reported.
Results
EGFR signaling and expression of immediate early genes
(IEGs) in SKBR3 cells
In order to determine the cellular dynamics following
EGF treatment (50 ng/mL) in serum starved SKBR3
cells, we extracted RNA, protein and chromatin at
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similar time points (Fig. 1a). EGFR signaling is initiated by
ligand activated receptor heterodimerization with HER2,
HER3 (human epidermal growth factor receptor-3) or
HER4 (human epidermal growth factor receptor-4) and
subsequent MAPK (mitogen-activated protein kinase)
phosphorylation. Therefore to analyze these events, we
subjected protein lysates to immunoblotting. EGFR phos-
phorylation increased within 15min of EGF treatment
and this was consistent with a concomitant increase in
pAKT (activated AKT/protein kinase B) and pERK1/2 (ac-
tivated Extracellular signal-regulated kinase 1/2 (ERK1/2))
(Fig. 1b). EGFR phosphorylation remained higher than
baseline levels throughout the 24 h EGF time course.
However, pAKT and pERK1/2 levels returned to basal
levels by 2 h and 1 h post-EGF treatment, respectively.
The transient activation of pAKT and pERK1/2 following
EGFR stimulation is consistent to previously published data
for similar experiments conducted in normal mammary
epithelial cells, MCF10A [17]. However, unlike similar
experiments conducted in MCF10A cells, SKBR3 cells
treated with EGF have a longer duration of higher than
basal levels of pERK1/2 and maintain nearly equal levels of
EGFR throughout the duration of the time course.
We next determined the regulation of IEGs in SKBR3
cells following EGF treatment. As has been observed in
HeLa and MCF10A cells [8], the treatment of SKBR3 cells
with EGF resulted in a robust induction of EGR2 (Early
growth response protein 2), JUN (Jun Proto-Oncogene) and
KLF2 (Krüppel-like Factor 2) (Fig. 1c) As the name for this
group of genes suggests, they peaked in expression imme-
diately after EGF treatment (1 h post) and rapidly
decreased at later time points, falling to below basal levels
by 4 h post-EGF treatment. Interestingly, EGR2, JUN and
KLF2 levels stabilized back to basal levels at later time
point’s post-EGF treatment (16 h–24 h).
mRNA-sequencing (RNA-seq) of SKBR3 cells treated with
EGF
Previous EGF time course experiments to determine glo-
bal changes in transcription utilized tiling arrays and/or
limited their investigation to earlier time points (< 8 h)
[8, 10–12]. Therefore to expand our current knowledge,
we explored gene expression in SKBR3 cells following
EGF treatment utilizing mRNA-sequencing (RNA-seq).
Serum starved SKBR3 cells were treated with EGF (50 ng/
mL) and RNA was isolated at time 0, 1 h, 2 h, 4 h, 6 h, 16 h
and 24 h post-EGF treatment (Fig. 1a). Following
alignment and transcript quantification, transcripts
with Fragments Per Kilobase of transcript per Million
mapped reads (FPKM) > 0.5 and those that were differ-
entially expressed by 2-fold or more compared to
untreated SKBR3 cells in biological replicates were
plotted in a heatmap according to their peak expression
or repression time (Fig. 2a and b). In total, 2038 tran-
scripts increased in expression by 2-fold or more com-
pared to untreated SKBR3 cells during the 24 h EGF
time course (Fig. 2a and Additional file 2: Table S1).
Fig. 1 Schematic of experimental outline and EGF time course. a EGF was added to HER2+ SKBR3 cells for indicated times. Total RNA, protein or
chromatin (*) was harvested for the indicated times. b Abundance of proteins involved in EGFR signaling were immunoblotted (n = 2 repeats). c
Levels of known immediate early genes (IEGs) were assayed by qPCR during an EGF time course (n = 3 repeats). *p-value < 0.1, **p-value < .01,
***p-value < .001 one-sided t-test for significant difference between Untreated and EGF treated samples
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We subdivided these transcripts into six clusters of
activated clusters (AC) 1–6, based on their peak expression
time (Fig. 2a). On the other hand, 2029 transcripts reduced
in expression by 2-fold or more compared to untreated
SKBR3 cells during the 24 h EGF time course (Fig. 2b and
Additional file 3: Table S2). These transcripts were also sub-
divided into six clusters of repressed clusters (RC) 1–6,
based on their peak repression time (Fig. 2b). All clusters of
genes were statistically significant (p-value < 0.001) when
compared to transcript expression in untreated serum
starved SKBR3 cells (Additional file 4: Figure S1).
Early activated transcripts (< 2 h)
Activated cluster 1 (AC1) contains 139 transcripts that
peaked in expression 1 h post-EGF treatment (Fig. 2a).
Gene ontology (GO) and Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway analysis of AC1 transcripts
confirmed that EGFR stimulation activated transcripts
involved in cell cycle function, gene regulation and MAPK
and TNF signaling pathways (Fig. 2c and d). AC1 contains
transcripts that have been previously classified as IEGs
(FOS (Fos Proto-Oncogene), JUN, NR4A1 (Nuclear Receptor
Subfamily 4 Group A Member 1) and EGR1 (Early growth
response protein 1)) and DEGs (KLF2 (Kruppel Like Factor
2), Dual Specificity Phosphatase 1, 4, 5, and 8 (DUSP1,
DUSP4, DUSP5 and DUSP8)) (Additional file 2: Table S1)
[8, 12]. ZFP36, also known as TTP (zinc finger protein
36 homolog) was also in AC1. ZFP36 has previously
been shown to regulate IEGs post-transcriptionally by
promoting the degradation of IEGs like FOS [8]. There-
fore, it is likely that in HER2+ SKBR3 cells, ZFP36 is
also an attenuator of EGFR signaling at the post-tran-
scriptional level. In short, a 1 h EGF treatment of
SKBR3 cells activated genes that are known to promote
and antagonize MAPK signaling.
AC2 contains 175 transcripts, whose activation peaked
2 h post EGF treatment, and these genes are known as
transcriptional repressors (Fig. 2a, c and Additional file 2:
Table S1). Examples of these transcripts are MAFF (MAF
BZIP Transcription Factor F), ID1 (DNA-Binding Protein
Inhibitor ID-1), Kruppel-Like Factor 10, 4, 7 (KLF10,
KLF4, KLF7), and EZH2 (Enhancer Of Zeste 2 Polycomb
Repressive Complex 2 Subunit). MAF (MAF BZIP Tran-
scription Factor) proteins are basic leucine zipper (bZIP)
family of transcription factors that have activator and re-
pressor functions in various tissues [18]. The function of
MAFF in EGFR signaling remains largely unexplored,
although ectopic expression of MAFF inhibited EGF
driven reporter activity [8]. Kruppel-like factor (KLF)
family of transcription factors are known downstream
targets of EGFR signaling and, like MAFF, function as
both activators and repressors through their interactions
with histone modifying complexes such as p300/CBP
(E1A binding protein p300/ CREB-binding protein), CtBP
(C-terminal-binding protein) and Sin3A (Histone Dea-
cetylase Complex Subunit Sin3a) [8, 19].
Fig. 2 EGF RNA-seq time course and GO terms. a EGF was added for indicated times in serum starved SKBR3 cells. RNA-seq was conducted.
Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values were generated using Cufflinks. And transcripts whose expression
was induced or b repressed to at least twice (in biological replicates) the baseline level were graphed according to when they reached their peak
or summit in expression AC = activated cluster RC = repressed cluster. Only FPKM values of greater than 0.5 were kept. The number of each
transcript in each cluster is indicated in parenthesis. c Gene ontology (GO) terms and d KEGG Pathways as reported by HOMER
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Late activated transcripts (24 h)
AC6 contains 955 transcripts and these transcripts
play a role in extracellular matrix organization, cell
junction organization and cell-cell adhesion (Fig. 2a, c
and Additional file 2: Table S1). The transcripts in
AC6 are indicative of cellular migration and focal
adhesion pathways activation (Fig. 2d). Some of the
genes in AC6 are known EGFR targets, such as MMP9
(Matrix Metallopeptidase 9), ITGA5 (Integrin Subunit
Alpha 5), KRT17(Keratin 17) [8, 10, 20]. However,
some have never been described as downstream EGFR
targets, such as Claudin (CLDN) family members
CLDN9 and CLDN12. Claudin proteins are known to
localize to tight junctions, however some Claudin mem-
bers are known to promote migration and metastasis [21].
FHL2 (Four-and-a-half LIM domains protein 2) was one
of the most differentially expressed genes at 24 h post-
EGF treatment, with an initial increase in expression 2 h
post-EGF treatment (Additional file 2: Table S1). FHL2 is
known to be a modulator of transcription that also has
additional roles in promoting signal transduction and cell
migration [22]. Wingless-Type MMTV Integration Site
Family, Member 9A (WNT9A) followed the same trend as
FHL2, initially increasing in expression at 2 h post-EGF
treatment (Additional file 2: Table S1). WNT9A, a non-
canonical WNT, is known to play role in morphogenesis,
development and proliferation inhibition, but its function
in HER2+ breast cancer is unknown [23–25]. Lastly, 10
S100 family of genes (12 transcripts) peaked in expression
24 h post-EGF treatment, but some had initial differential
gene expression as early as 4 h post-EGF treatment (Fig. 5).
Regulation of S100 genes will be discussed below.
Late repressed transcripts (24 h)
RC6 contains 846 transcripts and these transcripts play
a role in cell cycle and DNA replication (Fig. 2b,c and
Additional file 3: Table S2). The genes in RC6 are func-
tional components in MCM (minichromosome main-
tenance) complex formation and DNA replication
initiation (Fig. 2d). MCM2, MCM3, MCM4, MCM5,
MCM6 and MCM7 are all repressed 24 h post-EGF
treatment. In addition to MCM transcripts, PCNA
(Proliferating cell nuclear antigen), CDC25A (M-phase
inducer phosphatase 1), CDC45 (Cell Division Cycle
45), E2F Transcription factor 1 and 2 (E2F1, E2F2), and
CDT1 (DNA replication factor) are also in RC6. EGFR
signaling has been known to decrease 3H-Thymidine
incorporation in EGF treated breast cancer cells,
including SKBR3 cells [26]. This is probably due to the
potent activation of CDKN1A (p21), an inhibitor of G1
Cyclin Dependent Kinases (CDKs) [27, 28]. CDKN1A
peaked in expression 4 h post-EGF (i.e. AC3) and
remained higher than baseline levels throughout the
EGF time course. Therefore, we have identified the cell
cycle genes that are repressed as a result of EGF treat-
ment.Table 1 summarized those genes regulated by EGF.
Additional files 2 and 3: Table S1 and Table S2 lists all
genes modulated by EGF treatment.
Chromatin immunoprecipitation (ChIP) H3K18ac and
H3K27ac
In order to explore the underlying chromatin dynamics
following EGF treatment of SKBR3 cells, we conducted
ChIP-qPCR and assayed H3K18ac and H3K27ac enrich-
ment near the transcription start site (TSS) of three regu-
lated genes. We decided to specifically assay H3K18ac and
H3K27ac enrichment because (1) they are marks that are
exclusively deposited by co-activator paralogs P300/CBP
[29], (2) these marks are enriched in transcriptionally
active sites [14, 30], (3) these marks increase following
activation [12, 31], (4) H3K27ac has previously been
shown to increase near EGF activated genes [12] and (5)
H3K27ac is a marker of super-enhancers [32].
We first assayed H3K18ac and H3K27ac at a classic
IEG, JUN (Fig. 3a). H3K18ac increased 1 h post-EGF treat-
ment when compared to untreated cells. By 6 h post-EGF
treatment, H3K18ac fell below H3K18ac levels in un-
treated cells. H3K18ac levels rebounded above basal levels
24 h post EGF treatment. The oscillation of H3K18ac
following EGF treatment was recapitulated by H3K27ac
levels near the JUN TSS (Fig. 3a). H3K27ac levels also
increased 1 h post-EGF treatment compared to un-
treated cells, decreased below basal levels at 6 h
post-EGF treatment and returned to near basal levels at
24 h post-EGF treatment.
Table 1 Summary of genes regulated by EGF
AC1 AC2 AC3 AC6 RC2 RC5 RC6
FOS MAFF CDKN1A MMP9 CPNE1 MAX MCM2
JUN ID1 ITGA5 MCM3
NR4A1 KLF4 KRT17 MCM4
EGR1 KLF7 CLDN9 MCM5
DUSP1 KLF10 CLDN12 MCM6
DUSP4 EZH2 FHL2 MCM7
DUSP5 KDM3A WNT9A PCNA
DUSP8 KDM6B S100A5 CDC25A
ZFP36 S100A2 CDC45A
S100A3 E2F1
S100A10 E2F2
S100A6 CDT1
S100A13
S100A4
S100A7
S100P
S100A16
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We then assayed H3K18ac and H3K27ac near the TSS
of CPNE1 (Copine-1), a repressed gene in RC2 (Fig. 3a).
Surprisingly, H3K18ac increased near the TSS 1 h
post-EGF treatment and fell to near basal levels by 24 h
post-EGF treatment. The CPNE1 TSS had minimal
H3K27ac enrichment through the 24 h EGF time course.
Having observed H3K18ac increase near a repressed
gene, we assayed H3K18ac and H3K27ac near another
repressed gene, MAX (myc-associated factor X), that
peaked in repression 16 h post EGF treatment (RC5)
(Fig. 3a). Interestingly, both H3K18ac and H3K27ac
increased 1 h post-EGF treatment near the TSS of MAX.
H3K18ac and H3K27ac enrichment decreased dramati-
cally at 6 h and remained low at 24 h post-EGF treatment.
ChIP-sequence (ChIP-seq) H3K18ac and H3K27ac
The vast majority of ChIP-seq experiments in EGF
treated cells have focused on IEGs and immediately acti-
vated enhancers [12, 14]. Therefore, we decided to con-
duct ChIP-seq for H3K18ac and H3K27ac and to look at
all genes (Fig. 3b, c, and d). There were over 60,000
H3K18ac peaks in SKBR3 cells at every time point
except at 6 h post-EGF treatment (Fig. 4b and Table 2).
Moreover, the majority of H3K18ac peaks were shared
between untreated cells and all times post-EGF treatment
(Fig. 4b and Table 1). Most H3K18ac peaks that were
present following EGF treatment were not at new sites.
H3K27ac enrichment has previously been analyzed in
EGF treated HeLa cells [12, 14]. HeLa cells are cervical
adenocarcinoma cells and the location of H3K27ac could
vary significantly from cell type to cell type [32]. There-
fore, we decided to analyze H3K27ac in SKBR3 cells
treated with EGF (Fig. 3b and c). There were over 30,000
H3K27ac peaks at every time point assayed. Like for
H3K18ac peaks, most H3K27ac that were present follow-
ing EGF treatment were not at new sites. Although at 6 h
there were the fewest H3K27ac peaks, there was no stark
discrepancy in H3K27ac peak numbers during the time
course as there was for H3K18ac.
Fig. 3 H3K18ac and H3K27ac were mapped post EGF treatment. a EGF was added for indicated times in serum starved SKBR3 cells. Chromatin was
subjected to ChIP as indicated in the protocols (−/+SD). Enrichment was determined by using primers near the TSS of indicated genes. *p-value < 0.1
and **p-value <.01 t-test for significant difference between Untreated and EGF treated samples. b Total ChIP-seq peaks were counted for each
condition and overlapping peaks were identified for each timepoint within each ChIP. c The location of each peak was determined using CEAS
(sitepro) option. d H3K18ac and H3K27ac signals were mapped at all TSS by timepoint
Table 2 Summary of number of peaks in each ChIP-seq
H3K18ac peaks H3K27ac peaks
0 h 63,164 33,443
1 h 65,755 37,214
6 h 27,239 30,982
24 h 62,225 49,599
Nava et al. BMC Medical Genomics           (2019) 12:32 Page 7 of 15
The majority of H3K18ac and H3K27ac peaks in
untreated cells were in gene bodies (defined as TSS to
transcription termination site (TTS)), 52.8 and 50.3% of
total peaks, respectively (Fig. 3c). In general, a greater
proportion of H3K18ac peaks remained at intergenic
sites and a lower proportion of H3K18ac peaks in gene
bodies in EGF treated samples compared to untreated
cells (Fig. 3c). In contrast to H3K18ac peaks, H3K27ac
peaks decreased at intergenic regions and increased in
gene bodies in all EGF treated samples compared to
untreated cells (Fig. 3c). Lastly, H3K18ac and H3K27ac
peaks did not change significantly at promoters (defined
as < − 3 kb from TSS) during the EGF time course.
We next analyzed H3K18ac and H3K27ac levels and
distribution at all TSS. Untreated cells exhibited high
H3K18ac levels at ~ + 200 bp (Fig. 3d). This peak
increased at 1 h post-EGF treatment, dramatically de-
creased at 6 h and rebounded to baseline levels at 24 h.
There was also a much smaller H3K18ac peak at ~ − 250
that was similar in height for untreated cells and cells
treated for 1 h and 24 h. Cells treated for 6 h had the lowest
H3K18ac levels throughout the − 1000 to + 1000 window.
Similar to H3K18ac enrichment at the TSS of all
genes, H3K27ac increased at 1 h from − 1000 to + 1000,
but with similar peak locations to H3K18ac at ~ − 250
and ~ + 200. These H3K27ac peaks decreased at 6 h to
below H3K27ac peaks in untreated cells. Similar to
H3K18ac peaks, H3K27ac peaks rebounded from their 6
h levels at 24 h. Unlike H3K18ac, cells treated for 24 h
had higher H3K27ac at all TSS than untreated cells.
H3K27ac signal at 1 h and 24 h post-EGF treatment were
similar at all TSS.
H3K18ac and H3K27ac at regulated genes
Having observed that H3K18ac and H3K27ac increased at
activated and repressed genes (Fig. 3a), we analyzed
H3K18ac and H3K27ac enrichment near the TSS of all
regulated genes (Fig. 4a). H3K18ac and H3K27ac ChIP-seq
data closely resembled ChIP-qPCR data at JUN, CPNE1
and MAX (Figs. 3A and Additional file 5: Figure S2).
Fig. 4 H3K18ac, H3K27ac and transcription factor binding sites (TFBS) near TSS of clusters. a Genes in each cluster from Fig. 2 were subjected to
CEAS analysis. b Motif search results as indicated by HOMER search from -300 bp to + 50 bp of each cluster. All motifs shown were enriched at
p-value <.01
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Regardless of peak time, all activated clusters gained
H3K18ac and H3K27ac near the TSS by 1 h post-EGF
treatment. AC2 genes had the highest H3K18ac peak near
+ 200 bp at 1 h, followed by AC3 genes. Cells treated for 6
h had the lowest H3K18ac at all clusters. Surprisingly, genes
in RC1 had a slight increase in H3K18ac at 1 h compared
to untreated cells and the peak at ~ + 200 bp was higher in
RC1 than the one in AC1. All other repressed clusters had
no significant difference in H3K18ac between untreated
cells and those that were treated with EGF for 1 h and 24 h.
As has been previously shown [14], IEGs (AC1) gained
H3K27ac within 1 h of EGF treatment (Fig. 4a). Like
H3K18ac peaks at regulated genes, cells treated for 6 h
had the lowest H3K27ac levels near the TSS at all regu-
lated genes (Fig. 4a). Unlike H3K18ac at regulated genes,
H3K27ac levels were clearly higher near the TSS of all
regulated genes at 1 h and 24 h post-EGF treatment.
Interestingly, H3K18ac and H3K27ac trends were similar
in that they either increased or stayed near baseline
levels at 1 h, decreased at 6 h and at 24 h were either
similar to baseline levels or higher than baseline levels.
However, in general, H3K27ac peaks were higher near
activated genes compared to repressed genes (Fig. 4a).
Interestingly, and like H3K18ac, RC1 genes gained more
H3K27ac at 1 h and 24 h than AC1 genes at the same
time points.
Enriched motifs
Co-activator paralogs P300/CBP are recruited to gen-
omic sites through their interactions with sequence
specific proteins (i.e. transcription factors) or through
their bromodomain. Once recruited, P300/CBP can
deposit acetylation marks on histones (e.g. H3K18ac and
H3K27ac) and non-histone proteins [33]. Therefore, to
determine what transcription factor binding sites are
present at the various regulated clusters of genes we
analyzed the window from − 300 to + 50 of all regulated
genes by cluster (Fig. 4b). AC1, AC2 and AC6 all con-
tained transcription factor binding sites for transcription
factors known to be immediately downstream of EGFR
signaling, such as Activating Transcription Factor 1, 3, 7
(ATF1, ATF3, ATF7), SRF (C-Fos Serum Response
Element-Binding Transcription Factor), and FRA1 (Fos-
related antigen 1) (Fig. 4b). As expected, based on the
gene ontology data of RC6 (Fig. 2c), RC6 genes were
enriched for E2F family binding sites. Even though they
were not the most significantly enriched at all clusters,
every cluster contained binding sites for transcription
factors known to be downstream of EGFR signaling
(Fig. 4b and Additional file 6: Figure S3). One possibility
is that EGFR signaling promotes the recruitment of
P300/CBP to every regulated gene regardless of whether
there is consequential transcription.
EGF activates S100 genes
Looking closer at AC6, we observed that EGF activated
several S100 gene family transcripts from S100A5,
S100A2, S100A3, S100A10, S100A6, S100A13, S100A4,
S100A7, S100P and S100A16 (Fig. 5a). S100 proteins are
Ca2+ sensors that function in tumorigenic processes such
as cell migration, metastasis, proliferation and immune
evasion [16]. All S100 transcripts in AC6 increased grad-
ually during the EGF time course. S100A2 became acti-
vated 2-fold by 2 h post EGF treatment, while transcripts
from S100A5 and S100A3 became activated 2-fold or
more by 4 h post EGF treatment. The rest of the S100
transcripts reached the cutoff (i.e. 2-fold over untreated
cells) after the 4 h time point.
Out of 21 S100 genes, 17 are found on chromosome 1
in a 2Mb region known as the epidermal differentiation
complex (EDC) [16]. We looked closer at H3K18ac and
H3K27ac in a genomic region containing S100A6,
S100A5, S100A4 and S100A3 (Fig. 5b). H3K18ac levels
increased in the S100A6 gene body at 1 h, even though
H3K18ac peaks remained similar near the TSS. There
was an overall decrease in H3K18ac at 6 h throughout
the genome. H3K18ac levels recovered to near basal
levels at the S100A6 TSS at 24 h. In contrast to
H3K18ac, H3K27ac levels increased dramatically at the
TSS and in the S100A6 gene body within 1 h and stayed
elevated throughout the EGF time course. The anno-
tated S100A5 TSS contained low H3K18ac levels at all
time points but did contain a noticeable H3K18ac peak
within the gene body in untreated cells and cells treated
for 1 h. On the other hand, H3K27ac levels increased
robustly throughout the S100A5 coding region within 1
h post-EGF treatment and remained elevated during the
time course. H3K18ac levels at and near S100A4 were
similar in untreated cells and cells treated for 1 h and 24
h. In contrast, H3K27ac levels at and near S100A4
increased at 1 h and remained elevated compared to
H3K27ac levels in untreated cells.
Given the concomitant increase in S100 gene family
transcripts and histone acetylation levels we hypothe-
sized that S100 genes are direct EGFR signaling tran-
scriptional targets. In order to address this we analyzed
previously published ChIP-seq data for pol2 [12]. Pol2
increased in the gene body and/or near the TSS at
S100A2, S100P, S100A16 and S100A6 within 20 min of
EGF treatment in HeLa cells (Fig. 5c). Lastly, pol2
increased near the TSS of S100A2 and S100P in the
sense and anti-sense direction.
To confirm our finding from sequencing analysis we
separately treated SKBR3 and BT474 (another
HER2-positive breast cancer cell line) with EGF and
conducted RT-qPCR. The data showed that S100A5,
S100A6 and S100A10 were all upregulated upon EGF
treatment (Fig. 5d). We could not confirm upregulation
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of S100A2 by EGF in SKBR3, but it was significantly
upregulated in BT474 (Fig. 5d). We also did not con-
firm activation of S100A3 in any of the cell lines (data
not shown).
S100A genes and Trastuzumab resistance
To examine the contribution of S100 genes in HER2-
overexpressing breast cancer cells resistance to trastuzu-
mab, we determined the levels of S100 genes in a tras-
tuzumab resistant cell line SKBR3/100–8. SKBR3/100–8
was generated from SKBR3 through clonal selection in
our laboratory. Besides acquired resistance to trastuzu-
mab, SKBR3/100–8 cells display an EMT phenotype and
express higher levels of EGFR when compared to
parental SKBR3 cells [7]. SKBR3/100–8 cells express
significantly higher levels of S100A2 and S100A6 when
compared to parental SKBR3 cells. SKBR3/100–8 cells
also expressed 1.5-fold higher levels of S100A10 relative
to controls (Fig. 6a).
Our ChIP-seq data showed that EGF treatment in-
duced higher expression levels of S100A genes and this
coincided with an increase in H3K18ac and H3K27ac.
Specifically, H3K18ac and H3K27ac levels increased at the
TSS of S100 genes and in the S100A6 gene body within 1
h and stayed elevated throughout the EGF time course. To
determine whether P300/CBP activity had an effect on the
expression of S100 genes in HER2-overexpressing breast
cancer cells, we treated SKBR3/100–8 cells with A-485, a
selective small-molecule inhibitor of P300/CBP acetylase
activity, and examined expression of S100 family genes by
RT-qPCR. The data showed that inhibition of P300/CBP
activity decreased expression of S100A2, S100A5 and
S100A6 significantly in SKBR3/100–8 (Fig. 6b). The
level of S100A10 was not affected by inhibition of
P300/CBP.
Since S100A6 consistently demonstrated higher
levels in all three lines we tested, we sought to deter-
mine the role of S100A6 in HER2-overexpressing
breast cancer cells and in EGF/EGFR cell signaling
through siRNA knockdown experiments. First we
treated SKBR3 cells with an siRNA directed against
S100A6 and then treated the cells with EGF. The data
showed that knockdown of S100A6 itself did not affect cell
Fig. 5 EGF upregulates S100 gene family. a Bar graphs are log2 ratios of (timepoint/baseline). *p-value < 0.1, **p-value < .01, ***p-value < .001 as
reported by Cufflinks b. IGB browser view at locus containing S100A6, S100A5, S100A4 and S100A3. Red arrows indicate locations near annotated TSS
for S100 genes. c Pol2 enrichment at S100 genes before and 20min after EGF treatment in HeLa cells using data from Gardini et al. [12]. d SKBR3 and
BT474 cells were serum starved for 16 h and then treated with or without EGF for 24 h. RNA from those cells were used to examine the indicated the
levels of S100A genes by RT-qPCR. The bars indicated relative levels of those S100A genes adjusted for 18S. Each bar was mean of three values plus
standard deviation. **P < 0.01 compared to non-EGF treatment
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growth, however, it did inhibit EGF-induced cell growth
(Fig. 6c).
Next, we conducted S100A6 knockdown in trastuzu-
mab resistant cells, SKBR/100–8. Knockdown of S100A6
decreased EMT driver, Twist1 (Fig. 6d). This suggests a
role for S100 genes, specifically S100A6, in the migratory
phenotype observed in HER2-overexpressing breast
cancer cells with acquired trastuzumab resistance.
Discussion
Prior explorations into EGFR mediated modulation of
transcription utilized outdated technologies or limited
analysis to early time points following EGFR stimulation
[8, 10, 11, 13]. Furthermore, previous investigations
utilized cell lines such as HeLa, MCF10A and human
keratinocytes that are not dependent on EGFR and HER2
for survival, as these cell lines are insensitive to trastuzu-
mab treatment [34, 35]. In contrast, SKBR3 (HER2+) cells
are sensitive to trastuzumab and rely on HER2 for survival
[34, 36]. This makes SKBR3 cells a better model system to
study clinically relevant EGFR signaling.
The analysis contained herein implemented NGS tech-
nologies to interrogate the transcriptome and chromatin
landscape of SKBR3 cells following EGF treatment. We
found that EGFR stimulation, over a carefully conducted
EGF time course, regulated over 4000 transcripts, with
similar numbers becoming activated (2038) or repressed
(2029) by 2-fold or more relative to untreated cells. We
observed, as has been previously shown, a wave of tran-
scriptional activation and repression following EGF treat-
ment (Fig. 2a and b). Our analysis of the RNA-seq data
further expanded on current knowledge by searching for
fluctuations in transcript abundance (and not gene expre-
ssion), which better captures mRNA diversity [11].
EGF treatment of SKBR3 cells activated both immediate
early genes (IEGs) and delayed early genes (DEGs) within
1 h, consistent with previous work on other cell lines. The
transient activation of pAKT and pERK1/2 following EGFR
stimulation is consistent to previously published data for
similar experiments conducted in normal mammary epi-
thelial cells, MCF10A. However, unlike similar experiments
conducted in HeLa and MCF10A cells [17], SKBR3 cells
treated with EGF have a longer duration of higher than
basal levels of pERK1/2 and maintain nearly equal levels of
EGFR throughout the duration of the time course.
Previous experiments showed that EGF stimulation of
MCF10A activated DUSP5 [8]. In HeLa cells, EGF treat-
ment activated DUSP1, DUSP2 and DUSP5. DUSP (dual
specificity phosphatase) family of proteins dephosphorylate
phospho-serine, phospho-threonine and phospho-tyrosine
Fig. 6 S100A genes are associated with trastuzumab resistance. a The levels of the indicated S100A genes in wild type SKBR3 (SKBR3 wt) and
trastuzumab resistant cells, SKBR3/100–8 were examined by RT-qPCR. The bars indicated relative expressing levels of the indicated S100A genes
adjusted for 18S. Each bar indicated mean of three values plus standard deviation. **P < 0.01 compared to the levels of the indicated S100A
genes in SKBR3 wt. b SKBR3/100–8 cells were treated with 10 μM of A485 for 24 h and the levels of the indicated S100A genes were determined
by RT-qPCR. The bars indicated relative expressing levels of the indicated S100A genes adjusted for 18S. Each bar indicated mean of three values
plus standard deviation. **P < 0.01 compared non-treated cells. c SKBR3 cells were plated in 96 well plate and treated with siRNA S100A6 for 2
days, and then 20 μg of EGF were added into culture for additional 24 h. Cells viability of each condition was measured by MTT assay. The bars
were mean of 6 values plus standard deviation. **P < 0.01 compared to no EGF and sRNA treatment. d SKBR3/100–8 cells were treated with or
without siRNA S1006 for 72 h and then RNA was extracted. The levels of S100A and TWIST1 were examined by RT-qPCR. The bars indicated
relative expressing levels of S100A6 and TWIST1 genes adjusted for 18S. Each bar indicated mean of three values plus standard deviation.
**P < 0.01 compared non-siRNA treated cells (Scrambled)
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residues on their substrates and they are known to
antagonize MAPK signaling [37]. In addition, ZFP36
(ZFP36 Ring Finger Protein) and ZFP36L1 (ZFP36 Ring
Finger Protein Like1) also became activated within 1 h.
ZFP36 and ZFP36L1 are known to destabilize AU-rich
element-containing (ARE) transcripts and ZFP36 has previ-
ously been shown to promote FOS degradation [8]. In
addition, there is evidence that some DEGs, such as the
DUSP (Dual-specificity phosphatase) proteins, attenuate
EGFR signaling and it is conceivable that in HER2+ SKBR3
cells the same is true. Therefore, it is likely that similar
transcriptional dynamics exist in SKBR3 and HeLa cells
during the early phase of EGFR stimulation. In short, the
RNA-seq data for AC1 are consistent with previously pub-
lished data sets but add to the body of literature of IEGs
downstream of EGFR stimulation.
KDM3A (Lysine Demethylase 3A) and KDM6B (Lysine
Demethylase 6B) are demethylases involved in removing
repressive H3K27 methyl marks [38], and they clustered
into AC2 (Additional file 2: Table S1). Given the robust
induction of H3K27ac at activated and repressed genes it
is possible that KDM6B plays a role in removing H3K27
methyl marks prior to the deposition of H3K27 acetylation
marks. Mapping genome-wide H3K27 methyl modifica-
tions remains uninvestigated in EGF treated SKBR3 cells.
This is made more interesting by noting that EZH2 also
clustered into AC2 (Additional file 2: Table S1). EZH2
(Enhancer Of Zeste 2 Polycomb Repressive Complex 2
Subunit) is a component of the Polycomb Repressive
Complex 2 (PRC2), which is involved in depositing
H3K27me3 (histone H3 lysine 27 trimethylation) marks
and therefore silencing chromatin [39]. Therefore, deter-
mining the genome-wide localization of KDM3A, KDM6B
and EZH2 during EGFR stimulation could provide in-
sights into additional mechanisms of gene regulation
during EGFR signaling.
The transcripts in AC6 play a role in extracellular matrix
organization, cell junction organization and cell-cell adhe-
sion (Fig. 2c). EGF is known to induce cell migration in
several cell lines, including HeLa, MCF10A and human
keratinocytes. Our RNA-seq data adds to the number of
genes downstream of EGF that could be involved in cell
migration. WNT9A, a gene in AC6, is induced over 2-fold
relative to untreated cells within 2 h of EGF treatment.
WNT9A is known to affect morphogenesis in several
species and in different cell types [40–42]. In addition,
WNT9A is expressed at much higher levels in JIMT1 (a
trastuzumab resistant cell line) compared to SKBR3 cells
(a trastuzumab sensitive cell line) (data not shown).
An interesting group of transcripts in AC6 belong to
the S100 gene family (Additional file 2: Table S1). EGF
induced transcripts, by 2-fold or more relative to
untreated cells, of 10/21 S100 genes encoded in the
human genome. The increase in H3K18ac and H3K27ac
levels following EGFR stimulation was consistent with
chromatin regulation near the S100-gene-containing
locus on chromosome 1 (Fig. 5b). Moreover, the recruit-
ment of pol2 to several S100 gene family members
within 20 min of EGF treatment in HeLa cells, suggests
that some S100 genes are direct EGFR targets (Fig. 5c).
Furthermore, our data confirmed that S100A6 and
S100A2 were significantly increased in trastuzumab
resistant breast cancer cells, SKBR3/100–8 (Fig. 6a).
Inhibition of P300/CBP by A485 significantly downre-
gulated S100A2, S100A5 and S100A6 in SKBR3/100–8
(Fig. 6b). Trastuzumab resistance can develop from
increased HER family receptor signaling. Trastuzumab
reduces HER2-mediated signaling, but it may not
inhibit signaling from other HER2 family receptors’
crosstalk, such as EGFR (HER1) /HER2 [43]. In con-
trast to HER2-negative breast cancer, HER2-positive
breast cancer expresses higher levels of EGFR [44] and
exhibits increased signaling from HER family receptors,
such as EGFR, as well as EGFR/HER2 crosstalk [45].
These are some of the molecular mechanisms that
contribute to trastuzumab resistance. Data from our
laboratory showed an increased expression of EGFR in
HER2-overexpressing breast cancer cells that had
acquired resistance to trastuzumab [7]. Altered EGFR
signaling in tumors could result in phenotypic changes
and transcriptional changes which could promote EMT,
and increase cell proliferation, invasiveness and in-
creased motility [46]. Breast cancer cells undergoing
EMT also exhibit a drug and trastuzumab resistance
phenotype [7, 47–49]. S100A6 has been suggested to
promote EMT through β-Catenin in a pancreatic can-
cer cell line [50]. We also showed in this study that
knockdown of S100A6 by siRNA in SKBR3/100–8 also
decreased the expression of EMT driver, Twist1 (Fig. 6d).
RNAi mediated depletion of S100A6 also inhibited
EGF-induced cell growth (Fig. 6c). The data suggests that
EGF mediated induction of S100 genes could be a
mechanism by which HER2-overexpressing breast cancer
cells develop resistance to trastuzumab. S100A6 could be
potential target for treating HER2 and EGFR positive
breast cancer.
Although we did not assess migratory characteristics, it
is well documented that EGFR stimulation causes a migra-
tory phenotype in various cell lines [8, 9]. The transcrip-
tional profile illustrated in our data suggests that this is
also the case in SKBR3 cells. This is interesting because of
the strong association observed between Epithelial-
Mesenchymal-Transition and trastuzumab resistance
[51, 52]. Moreover, the multidrug resistance phenotype
is enhanced in breast cancer cells that have activated
MAPK/ERK pathways [53]. Interestingly in our experi-
ments, pEGFR remained higher than baseline levels
throughout the 24 h period, even though pERK1/2 and
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pAKT were back to baseline levels by 1–2 post-EGF treat-
ment, suggesting that other pathways could become acti-
vated by EGFR signaling.
In addition, S100 genes are known to be overexpressed
in certain cancers and have been the focus of research
groups interested in developing novel drug targets [16].
To that end, paquinimod and tasquinimod have been
tested as small molecule inhibitors of S100A8 and
S100A9. Tasquinimod has demonstrated promising
results, as phase II and phase III clinical trials have indi-
cated positive relapse free survival (RFS) in prostate
cancer patients [54, 55]. Additional research on the
function of S100 proteins in HER2+ breast cancer
disease must be conducted and is currently underway in
our laboratory.
Our H3K18ac and H3K27ac ChIP-seq data, demon-
strates for the first time that the chromatin landscape has
been assessed in an EGF treatment time course of HER2+
breast cancer cells. H3K18ac increased near the TSS of all
activated genes and at RC1 within 1 h, suggesting that
regardless of when genes peaked in expression, the chro-
matin landscape was rapidly altered (Fig. 4a). On the other
hand, H3K27ac levels increased at all regulated genes and
remained higher than H3K27ac levels in untreated cells at
1 h and 24 h post-EGF treatment (Figs. 3d and 4a). This
strongly suggests that chromatin regulation does not
account for all of the fluctuations in gene expression
observed in EGF treated SKBR3 cells. To that end, other
groups have demonstrated that microRNAs play a role in
modulating mRNA’s in EGF treated MCF10A cells [9, 13].
Nonetheless, studying the role of microRNAs in EGF
treated SKBR3 cells using NGS technologies remains
unexplored and might provide key differences of post-tran-
scriptional regulation of gene expression. Moreover, other
groups have shown that gene expression in EGF treated
cells is regulated at the “pause” step in transcription [12,
15]. Therefore, it would be interesting to explore pol2
recruitment in EGF treated SKBR3 cells. Lastly, given
the oscillations in H3K18ac and H3K27ac during the
EGF time course, it would be insightful to know the
genome-wide locations of P300/CBP, the acetylases that
deposit those marks.
Conclusion
We report here the first study to examine the modula-
tion of gene regulation by EGFR/HER2 in a clinically
relevant HER2+ breast cancer cell line. Dysregulated
gene expression is a hallmark of cancer [56]. Oncogenic
signaling directly affects chromatin structure, as our data
has demonstrated [57]. The implementation of NGS
technologies to the field of cancer biology has provided
mechanistic insights into how cancer cells differ from
normal cells. This has facilitated the discovery of novel
drug targets. Trastuzumab resistance is a clinical reality,
with many patients facing recurring breast cancer
disease [5, 6]. In addition, HER2+ breast cancer disease
is discovered in more advanced stages in African-American
women at a point when trastuzumab therapy is less
effective [58, 59]. Therefore, our results have added to the
list of likely drug targets, some of which we are already
pursuing. Targeting S100 proteins may prevent EGF
induced tumor cell growth and metastasis and can
complement trastuzumab therapy.
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